ArQule Inc. | |
Stock Exchange | NASDAQ Stock Market |
EPS |
$0.17 |
Market Cap |
$1.34 B |
Shares Outstanding |
118.84 M |
Public Float |
97.53 M |
Address |
One Wall Street Burlington Massachusetts 01803 United States |
Employees | - |
Website | http://www.arqule.com |
Updated | 07/08/2019 |
ArQule, Inc. is a clinical-stage biopharmaceutical company, which engages in the research and development of targeted therapeutics to treat cancers and rare diseases. The company discovers, develops and commercializes novel small molecule drugs in areas of unmet need that will dramatically extend and improve the lives of its patients. Its proprietary pipeline includes ARQ 531, Derazantinib, Miransertib, ARQ 751, ARQ 761. |